Just before Christmas, the US Food and Drug Administration (FDA) announced that it had approved an injectable formulation of the HIV drug cabotegravir for use as PrEP. The drug, to be given as an injection every two months, will be branded as Apretude in the US. Although FDA approval came earlier than expected, they could have hardly rejected it.
When the FDA approved injectable cabotegravir and rilpivirine as an HIV therapy (branded as Cabenuva in the US) nearly a year ago, it did so on the basis of the drugs being ‘non-inferior’ to equivalent daily pills. They suppressed HIV as well as, but no better than, conventional antiretrovirals.
But in the two pivotal studies conducted by the HIV Prevention Trials Network (HPTN) that compared injectable cabotegravir’s efficacy to oral PrEP, it was spectacularly better at preventing HIV.
Read the full story at Aidsmap.
Source : Aidsmap
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.